Characteristics of Ischemic Stroke Despite Oral Anticoagulant Use For Atrial Fibrillation

被引:2
作者
Dube, Marie-Christine [1 ,2 ]
Ducroux, Celina [1 ,2 ]
Daneault, Nicole [1 ,2 ,3 ]
Deschaintre, Yan [1 ,2 ,3 ]
Jacquin, Gregory [1 ,2 ,3 ]
Odier, Celine [1 ,2 ,3 ]
Stapf, Christian [1 ,2 ,3 ]
Poppe, Alexandre Y. [1 ,2 ,3 ]
Romanelli, Giovanni [4 ]
Gioia, Laura C. [1 ,2 ,3 ]
机构
[1] Univ Montreal, Fac med, Dept Neurosci, Montreal, PQ, Canada
[2] Ctr Hosp Univ Montreal, Dept Med Neurol, Montreal, PQ, Canada
[3] Ctr Rech Ctr Hosp Univ Montreal CRCHUM, Neurovasc Grp, Neurosci Axis, Montreal, PQ, Canada
[4] Ctr Hosp Univ Montreal, Dept Med Cardiol, Montreal, PQ, Canada
关键词
Acute stroke; anticoagulation; treatment failure; ANTITHROMBOTIC THERAPY; MANAGEMENT; RISK; ECHOCARDIOGRAPHY; EFFICACY; SOCIETY; SAFETY;
D O I
10.1017/cjn.2024.3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Oral anticoagulation (OAC) prevents stroke in atrial fibrillation, yet a residual stroke risk remains. In this single-center retrospective analysis of acute ischemic stroke patients despite OAC, suboptimal OAC treatment is common (30%: inappropriate dosing (17%); patient non-adherence (13%)). Other causes of stroke included OAC interruption (14.5%), a competing stroke mechanism (11.0%), and undetermined breakthrough stroke in 44.5%. Overall, easily modifiable causes of ischemic stroke despite OAC are common. Accordingly, strategies to improve treatment compliance, including appropriate dosing along with guideline-based risk factor and periprocedural OAC management, should be emphasized to improve secondary stroke prevention in this patient population. Les accidents vasculaires cerebraux ischemiques et leurs caracteristiques, dans la fibrillation auriculaire, malgre l'anticoagulotherapie orale.Les anticoagulants oraux (AO) visent a prevenir la survenue d'accidents vasculaires cerebraux (AVC) dans le contexte de la fibrillation auriculaire, mais il persiste un risque residuel. Ainsi, dans une analyse retrospective de dossiers de patients ayant subi un AVC ischemique aigu, malgre les AO, realisee dans un centre de traitement, l'application sous-optimale de traitement par les AO s'est revelee chose courante (30 %; posologie inappropriee [17 %], non-observance therapeutique [13 %]). Par ailleurs, il existe d'autres causes possibles d'AVC, notamment l'interruption de l'anticoagulotherapie orale (14,5 %), la presence concomitante de mecanismes d'AVC (11,0 %) et la survenue d'AVC d'origine inconnue (44,5 %). Pourtant, plusieurs causes d'AVC ischemique, malgre les AO, sont facilement modifiables. Aussi faudrait-il mettre l'accent sur des strategies permettant d'ameliorer l'observance therapeutique, la prescription de regimes posologiques appropries ainsi que la prise en charge de facteurs de risque et de l'anticoagulotherapie orale en phase peri-interventionnelle, fondee sur des lignes directrices, dans le but rendre plus efficace la prevention secondaire des AVC dans ce groupe particulier de patients.
引用
收藏
页码:851 / 854
页数:4
相关论文
共 21 条
[1]   The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation [J].
Andrade, Jason G. ;
Aguilar, Martin ;
Atzema, Clare ;
Bell, Alan ;
Cairns, John A. ;
Cheung, Christopher C. ;
Cox, Jafna L. ;
Dorian, Paul ;
Gladstone, David J. ;
Healey, Jeff S. ;
Khairy, Paul ;
Leblanc, Kori ;
McMurtry, M. Sean ;
Mitchell, L. Brent ;
Nair, Girish M. ;
Nattel, Stanley ;
Parkash, Ratika ;
Pilote, Louise ;
Sandhu, Roopinder K. ;
Sarrazin, Jean-Francois ;
Sharma, Mukul ;
Skanes, Allan C. ;
Talajic, Mario ;
Tsang, Teresa S. M. ;
Verma, Atul ;
Verma, Subodh ;
Whitlock, Richard ;
Wyse, D. George ;
Macle, Laurent .
CANADIAN JOURNAL OF CARDIOLOGY, 2020, 36 (12) :1847-1948
[2]   CURRENT CONCEPTS Management of Antithrombotic Therapy in Patients Undergoing Invasive Procedures [J].
Baron, Todd H. ;
Kamath, Patrick S. ;
McBane, Robert D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (22) :2113-2124
[3]   Does the Left Atrial Appendage Morphology Correlate With the Risk of Stroke in Patients With Atrial Fibrillation? Results From a Multicenter Study [J].
Di Biase, Luigi ;
Santangeli, Pasquale ;
Anselmino, Matteo ;
Mohanty, Prasant ;
Salvetti, Ilaria ;
Gili, Sebastiano ;
Horton, Rodney ;
Sanchez, Javier E. ;
Bai, Rong ;
Mohanty, Sanghamitra ;
Pump, Agnes ;
Brantes, Mauricio Cereceda ;
Gallinghouse, G. Joseph ;
Burkhardt, J. David ;
Cesarani, Federico ;
Scaglione, Marco ;
Natale, Andrea ;
Gaita, Fiorenzo .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 60 (06) :531-538
[4]   Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS) [J].
Diener, Hans-Christoph ;
Easton, J. Donald ;
Granger, Christopher B. ;
Cronin, Lisa ;
Duffy, Christine ;
Cotton, Daniel ;
Brueckmann, Martina ;
Sacco, Ralph L. .
INTERNATIONAL JOURNAL OF STROKE, 2015, 10 (08) :1309-1312
[5]   Atrial Cardiopathy in the Absence of Atrial Fibrillation Increases Risk of Ischemic Stroke, Incident Atrial Fibrillation, and Mortality and Improves Stroke Risk Prediction [J].
Edwards, Jodi D. ;
Healey, Jeff S. ;
Fang, Jiming ;
Yip, Kathy ;
Gladstone, David J. .
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (11)
[6]   Residual Risk of Stroke and Death in Anticoagulant-Treated Patients With Atrial Fibrillation [J].
Freedman, Ben ;
Martinez, Carlos ;
Katholing, Anja ;
Rietbrock, Stephan .
JAMA CARDIOLOGY, 2016, 1 (03) :366-368
[7]  
Gladstone DJ., 2021, CAN J NEUROL SCI, V2020, P1
[8]   Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source [J].
Hart, R. G. ;
Sharma, M. ;
Mundl, H. ;
Kasner, S. E. ;
Bangdiwala, S. I. ;
Berkowitz, S. D. ;
Swaminathan, B. ;
Lavados, P. ;
Wang, Y. ;
Wang, Y. ;
Davalos, A. ;
Shamalov, N. ;
Mikulik, R. ;
Cunha, L. ;
Lindgren, A. ;
Arauz, A. ;
Lang, W. ;
Czlonkowska, A. ;
Eckstein, J. ;
Gagliardi, R. J. ;
Amarenco, P. ;
Ameriso, S. F. ;
Tatlisumak, T. ;
Veltkamp, R. ;
Hankey, G. J. ;
Toni, D. ;
Bereczki, D. ;
Uchiyama, S. ;
Ntaios, G. ;
Yoon, B. -W. ;
Brouns, R. ;
Endres, M. ;
Muir, K. W. ;
Bornstein, N. ;
Ozturk, S. ;
O'Donnell, M. J. ;
Basson, M. M. De Vries ;
Pare, G. ;
Pater, C. ;
Kirsch, B. ;
Sheridan, P. ;
Peters, G. ;
Weitz, J. I. ;
Peacock, W. F. ;
Shoamanesh, A. ;
Benavente, O. R. ;
Joyner, C. ;
Themeles, E. ;
Connolly, S. J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (23) :2191-2201
[9]   Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis [J].
Hart, RG ;
Benavente, O ;
McBride, R ;
Pearce, LA .
ANNALS OF INTERNAL MEDICINE, 1999, 131 (07) :492-+
[10]  
Kannel W.B., 1998, AM J CARDIOL, V82, p2N, DOI DOI 10.1016/S0002-9149(98)00583-9